preoperative consultation. Lord Bridge warned that denning what "a reasonable person in the patient's position" would consider a risk of sufficient significance that he should be told about it, would prove impractical, unrealistic and meaningless, and lead to unpredictable outcomes [2] . His warning appears to be supported by the findings of our survey.
Effect of nabilone on nausea and vomiting
Sir,-We read with interest the study undertaken by Lewis, Campbell and Barrowcliffe [1] in which they compared the effects of preoperative oral metoclopramide and oral nabilone on postoperative nausea and vomiting in patients undergoing total abdominal hysterectomy. We wish to comment on this study. First, the inclusion in the study of a formal control group receiving placebo, as opposed to using the findings of a previous survey regarding postoperative vomiting only after total abdominal hysterectomy, would have been most valuable. This would have provided a standardized baseline for interpretation of the results of the study, especially as there are no previously published reports on the use of cannabinoids for the treatment of postoperative nausea and vomiting, as noted by the authors.
Second, it has been demonstrated that the oral bioavailability of a 10 mg dose of metoclopramide varies between 32 % and 97 % [2] whereas that of nabilone 2 mg is 96 % [3] ; hence, in a group of patients receiving a fixed dose of oral metoclopramide, there is likely to be significant inter-patient variation in serum concentrations of the drug. In addition, in the treatment of cisplatininduced vomiting using high-dose metoclopramide, it has been demonstrated that in patients responding to this antiemetic therapy, a clear plasma concentration-antiemetic effect relationship can be shown [4] .
Third, it is interesting to note that in the recovery room, patients who had received metoclopramide before operation had higher nausea and vomiting scores and statistically significant increased opioid use than patients who had received nabilone. In the postoperative period, pain, opioid administration, and nausea and vomiting are linked, although opinion differs as to whether or not pain itself is associated with postoperative nausea and relieved by opioids [5] or whether parenteral opioids are associated with more nausea and vomiting than they relieve [6]. The difference in recovery room opioid requirements between the two groups of patients may be a manifestation of the analgesic effect of nabilone; this may make an indirect contribution to the antiemetic activity of the drug either by inherent analgesia or by an opioid-sparing effect.
Nabilone offers an effective alternative in the treatment of patients who experience chemotherapy-induced nausea and vomiting which is refractory to conventional therapy [7J. It will be interesting to see whether or not there is a role for nabilone in the treatment of postoperative nausea and vomiting. Further studies involving both single-dose and multiple-dosing schedules will be necessary before this can be decided. 
